Unter Telbivudin waren außerdem tendenziell höhere HBeAg-Verlust- (35% vs. 29%) und -Serokonversionsraten (30% vs.
A trend towards higher rates of HBeAg loss (35% vs 29%) and seroconversion (30% vs 25%) was also observed for telbivudine.